QRVO
6
2
URI
53
-2
HIG
67
4
DTE
50
3
MPC
47
3
MA
55
-7
PSA
51
-4
NOV
58
3
CAH
47
3
AA
51
3
LB
34
8
SYF
85
2
ETR
68
3
XYL
37
2
NTAP
64
2
GRMN
62
-3
MDLZ
34
2
WAT
47
5
JPM
63
-4
ADP
64
2
QRVO
6
2
URI
53
-2
HIG
67
4
DTE
50
3
MPC
47
3
MA
55
-7
PSA
51
-4
NOV
58
3
CAH
47
3
AA
51
3
LB
34
8
SYF
85
2
ETR
68
3
XYL
37
2
NTAP
64
2
GRMN
62
-3
MDLZ
34
2
WAT
47
5
JPM
63
-4
ADP
64
2
Financhill
Back

Black Diamond Therapeutics Quote, Financials, Valuation and Earnings

Invest. Do Good. Get Rewarded. Just $0.25/Share!

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
34

BDTX
Black Diamond Therapeutics

Last Price:
2.39
Seasonality Move:
21.01%

7 Day Trial

ALL ACCESS PASS

$ 7

Access The Stock Grader Trading Tool From "The King Of Quants"

More details here...

Black Diamond Therapeutics Price Quote

$2.39
-0.04 (-1.65%)
(Updated: November 21, 2024 at 2:55 PM ET)

Black Diamond Therapeutics Key Stats

Sell
34
Black Diamond Therapeutics (BDTX) is a Sell
Day range:
$2.38 - $2.56
52-week range:
$2.12 - $7.66
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
1.45%
Volume:
468.9K
Avg. volume:
647.2K
1-year change:
8%
Market cap:
$141.5M
Revenue:
$0
EPS:
$-1.33

How Much Does Black Diamond Therapeutics Make?

Data Unavailable

Is Black Diamond Therapeutics Growing As A Company?

Data Unavailable

Black Diamond Therapeutics Stock Price Performance

What Is Black Diamond Therapeutics 52-Week High & Low?

Black Diamond Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Black Diamond Therapeutics?

Is Black Diamond Therapeutics Cash Flow Positive?

  • What Is BDTX Cash Flow From Operations?
    Cash flow from operations (TTM) is -$61.2M
  • What Is Black Diamond Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $25.2M
  • What Is Black Diamond Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $1.4M

Black Diamond Therapeutics Return On Invested Capital

Data Unavailable

Black Diamond Therapeutics Earnings Date & Stock Price

Black Diamond Therapeutics Competitors

Black Diamond Therapeutics Dividend Yield

Black Diamond Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 21.5%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 4
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 14.50
Upside from Last Price: 496.71%

Major Shareholders

  • How many BDTX shares are owned by institutional investors?
    95.4M BDTX shares are owned by institutional investors
  • How many BDTX shares are owned by insiders?
    1.2M BDTX shares are owned by insiders